Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01013415 · ClinicalTrials.gov registry record · Phase 1
CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients
A Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT01013415: Completed Phase 1 study, sponsored by University of Pennsylvania.
NCT01013415 is a Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01013415, a Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to find out the safety and activity of an experimental anti-HIV treatment using autologous CD4-zeta gene-changed T cells and/or IL-2 (recombinant interleukin2).
Interventions
- DRUG HAART
- BIOLOGICAL T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2001-09 |
| Est. Completion | 2021-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01013415
The ClinicalTrials.gov registry entry for NCT01013415 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which HAART is the first listed.
NCT01013415 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01013415 about?
NCT01013415 is a clinical study titled "CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients". The purpose of this study is to find out the safety and activity of an experimental anti-HIV treatment using autologous CD4-zeta gene-changed T cells and/or IL-2 (recombinant interleukin2).
What is the current status of trial NCT01013415?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2001-09. Estimated completion is 2021-08.
What interventions are being tested in trial NCT01013415?
The interventions under investigation include: HAART (DRUG), T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT01013415?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.